TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Regen Biopharma ( (RGBP) ) just unveiled an update.
On October 2, 2025, Regen Biopharma, Inc. entered into consulting agreements with Dr. Harry Lander and CEO David Koos, granting each twenty million newly issued common shares subject to vesting, to support a planned Phase I clinical trial of HemaXellerate. This trial aims to assess the safety and efficacy of the therapy in patients with severe aplastic anemia, potentially impacting the company’s market position and stakeholder interests.
More about Regen Biopharma
Regen Biopharma, Inc. operates in the biotechnology industry, focusing on developing stem cell therapies. Its primary product, HemaXellerate, is a cellular composition derived from adipose tissue, aimed at treating drug-refractory aplastic anemia.
Average Trading Volume: 297,579
Technical Sentiment Signal: Strong Sell
Current Market Cap: $427.8K
See more data about RGBP stock on TipRanks’ Stock Analysis page.